VENUS MEDTECH-B2500.HKValuation Analysis

As of Oct 16, 2026, VENUS MEDTECH-B (2500.HK) trades at a negative P/E (-0.90x, due to a recent net loss), P/B of 0.27x, P/S of 1.63x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 2nd percentile over the trailing 10Y window (vs. 6th percentile over 3Y); P/S sits at the 4th percentile over the trailing 10Y window (vs. 8th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 6th percentile within its industry and the 19th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Relative to industry peers, its P/B shows a deeper discount than it does against the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. VENUS MEDTECH-B operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.